Intelligo

Private limited company · Oslo

NATTOPHARMA AS

ActiveWholesale of other food (46.380)

Founded
4 Nov 2004
Business address
Etasje 05, Mustads Vei 1, 0283 Oslo

The website has not been read for a card yet.

The life line 2004–2026

Operating revenue per year, with recorded events above. As a table

Operating revenue 2024: NOK 29.6m.

  1. Kapital§ 14
  2. Chair took office§ 07
  3. Founded§ 16

Sources: the Register of Company Accounts (company accounts), fetched 15 Nov 2026; the Brønnøysund Register Centre. Each event has the colour of the section it is in.

In brief

NATTOPHARMA AS is a private limited company in Oslo, founded in 2004, in the industry wholesale of other food. The chair of the board is Knut Christian Espeseth. In 2024 the company had NOK 29.6m in operating revenue and a net profit of NOK 35.6m. The largest owner is IMMUNOPHARMA AS with 100.0%.

Put together by Intelligo from the sections below; each figure stands with its source where it belongs.

Overview

§ 01 Latest changes

4 changes, latest 3 Nov 2026

  • Group affiliation changed False → True
  • Godkjent årsregnskap
  • Endring av revisor
  • IMMUNOPHARMA AS in as an owner with 100.0%

Source: the Brønnøysund Register Centre and Intelligo's own observations, fetched 15 Nov 2026 · All events →

Overview

§ 02 Worth knowing

1 point

  • OKEquity ratio 55.3%, above the industry median

Assumed: derived by Intelligo by fixed rules, not a credit rating. How we calculate

Overview

§ 03 Key figures

Revenue — in 2025

Revenue

—

— from 2024

20232025

Operating profit

NOK −340k

−101.4% from 2024

20232025

Net profit

NOK 869k

−97.6% from 2024

20232025

Equity

NOK 27.2m

+3.3% from 2024

20232025

Source: the Register of Company Accounts, read 15 Nov 2026 · The full accounts →

Finances

§ 04 Where the money comes from and goes

Financial year 2024

Of every krone of operating revenue in 2024:

  • Wages and social costs 12%
  • Depreciation 2%
  • Other operating costs 3%
  • Left as operating result 84%

Source: the Register of Company Accounts via areg.no, read 15 Nov 2026

Finances

§ 05 Financial health

Equity ratio 55.3%

RevenueNOK 29.6m Operating margin84.2% Equity ratio55.3% Revenue growth−84.9%
  • NATTOPHARMA AS, 2024
  • Industry median, assumed: NOK 2.9m · 1.6% · 24.2% · +5.7%

Equity NOK 26.3m55% of the assets (NOK 47.6m)

Source: the Register of Company Accounts, read 15 Nov 2026. The median is derived by Intelligo from 308 companies in 46.380 Wholesale of other food, not stated by the source.

Finances

§ 06 Accounts

21 years, latest 2025

NOK 1,0002023–25202520242023
Operating revenue—29,582196,104
Operating profit−34024,906116,381
Profit before tax86935,602129,359
Net profit86935,602110,359
Total assets32,95047,555234,034
Equity27,16026,29267,751
Liabilities5,78921,264166,284

Source: the Register of Company Accounts, read 15 Nov 2026 · All 21 years →

Management and ownership

§ 07 Officers

3 officers now

The board: 2 members

Source: the Brønnøysund Register Centre, read 23 Oct 2026 · All 3 roles, former ones too →

Management and ownership

§ 08 Signature, procuration and authorisations

Styrets leder alene eller to styremedlemmer i fellesskap.

May sign for the company:

Styrets leder alene eller to styremedlemmer i fellesskap.

Procuration: none registered.

The board has no authorisation in force now.

The signature is word for word from the register. Source: the Register of Business Enterprises, read 24 Aug 2026

Management and ownership

§ 09 Owners

1 shareholder · largest 100.0%

OwnerShare
IMMUNOPHARMA AS
100.0%

Source: the Tax Administration's Register of Shareholders as of 31 December 2025, read 31 Jul 2026 · All 1 owners →

Management and ownership

§ 10 Group

1 subsidiary

NATTOPHARMA AS parent company

The group 2023: operating revenue NOK 196.1m.

Share held. Source: the Tax Administration's shareholder register, fetched 31 Jul 2026 · The whole group →

Management and ownership

§ 11 Portfolio

Holds shares in 1 company

Source: the Tax Administration's Register of Shareholders, read 31 Jul 2026 · The whole portfolio →

Management and ownership

§ 12 Network

12 connections

  • Person
  • Company

2 people link NATTOPHARMA AS to 10 other companies: Kjetil Ramsøy 8 and Knut Christian Espeseth 3.

Source: the Brønnøysund Register Centre, read 23 Oct 2026 · Explore the network →

Events and registers

§ 13 Events

90 since 2015

Events per year

20152026

  • Notices193
  • Owners in and out10
  • Register changes1

Since 2015: 193 announcements, 1 register change and 2 new and 8 former owners. Most happened in 2020 and 2021.

Source: the announcements of the Brønnøysund Register Centre, the Tax Administration's Register of Shareholders, Doffin, TED and NAV, read 2 Nov 2026. Register changes are Intelligo's own observations. · All 90 events →

Events and registers

§ 14 Notices

193, latest 23 Jul 2026

  • Godkjente årsregnskap
  • Godkjente årsregnskap
  • Godkjente årsregnskap

Source: The Brønnøysund Register Centre's announcements ↗, read 2 Nov 2026 · All 193 →

Events and registers

§ 15 Charges

Not fetched yet

Events and registers

§ 16 Other registers

Found in 3 of 7

  • The Central Coordinating RegisterRegistered 27 Jan 2005
  • VATRegistered
  • The Register of Business EnterprisesRegistered 27 Jan 2005
  • The Cleaning RegisterNot registered
  • The Register of Staffing AgenciesNot registered
  • Smiley scheme, the Norwegian Food Safety AuthorityNot registered
  • The Financial Supervisory Authority's licence registerNot registered

Purpose: Direkte og via eierinteresser i andre selskaper å: Utvikle, distribuere og selge ernæringsprodukter og pharmasiprodukter, samt tilknyttede tjenester til dette.

Source: the Brønnøysund Register Centre, the Labour Inspection Authority, the Food Safety Authority and the Financial Supervisory Authority, each on its own, fetched 15 Nov 2026

Market

§ 17 Tenders

None registered

No tenders recorded.No public tenders won, lost or announced, in Doffin or TED. Checked 15 Nov 2026.

Market

§ 18 Vacancies

None registered

No vacancies.No open ads at NAV. Checked 15 Nov 2026.

Market

§ 19 Competitors

Industry code 46.380

The companies most like it:

Compare them

The selection is Intelligo's, not stated by the source: companies met in tenders and winners of tenders of the same kind, otherwise the same industry code, nearest in place and size. Source: the Brønnøysund Register Centre, Doffin and TED, fetched 15 Nov 2026 · All competitors → · Largest in the industry →

Last

§ 20 Questions and answers

6 questions

  • Who owns NATTOPHARMA AS?
    1 shareholder. It is IMMUNOPHARMA AS with 100.0%. § 09
  • What was the revenue in 2024?
    NOK 29.6m in the company. § 06
  • Who can sign for NATTOPHARMA AS?
    Styrets leder alene eller to styremedlemmer i fellesskap. § 08
  • Who is the auditor?
    FORVIS MAZARS AS, from 27 Jan 2005. § 07
  • Where is NATTOPHARMA AS based?
    Etasje 05, Mustads Vei 1, 0283 Oslo.
  • When was NATTOPHARMA AS founded?
    4 Nov 2004, registered in the Register of Business Enterprises 27 Jan 2005. § 16

The answers come from the sections linked to, with their sources.

01Latest changesOverviewContentsClose